AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development

February 22, 2019

CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development. Dr. Huttner brings over 15 years of clinical research and development and translational medicine experience to the LogicBio leadership team, as well as a clinical background in pediatrics and neonatology.

“Ken will be a core addition to our team as we advance our lead program for methylmalonic acidemia into the clinic,” said Fred Chereau, LogicBio’s President and Chief Executive Officer. “His experience in translational strategy and clinical development will help us deliver on our goal of bringing novel therapeutics to children with rare genetic diseases.”

Most recently, Dr. Huttner served as Vice President of Clinical Development at Bioverativ, where he was the clinical lead for a wide range of programs, including gene therapies. Prior to Bioverativ, Dr. Huttner was the Executive Director of Translation Medicine at Novartis Institutes for BioMedical Research. From 2010 to 2015, he served as Vice President of Clinical Development at Edimer Pharmaceuticals, Inc. He has also held medical director roles at CombinatoRx, Inc. and Interleukin Genetics, Inc. Dr. Huttner received his M.D. and Ph.D. in human genetics from Yale University. In his new role at LogicBio, he will lead IND-enabling studies and upcoming clinical trials for the Company’s lead therapeutic candidate, LB-001, and other programs in its pipeline.

“There is a strong commitment among the LogicBio team to deliver novel treatments to patients with severe genetic disease,” Dr. Huttner said. “Their GeneRide technology offers a promising new approach for precise and durable nuclease-free genome editing that leverages homologous recombination and powerful endogenous promoters. It’s exciting to join the team as they move toward the clinic.”

About LogicBio Therapeutics

LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene in a nuclease-free and promoterless approach by relying on the native process of homologous recombination to drive lifelong expression. Headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

Contacts: Investors: Michael Schaffzin Stern Investor Relations michael@sternir.com 212-362-1200

Media: Stephanie SimonTen Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333